Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iPD1 CD19 eCAR T cells (Peking University)
- Development stage
- Unknown
- Lead developer
- Beijing Mali Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
- Administration
- Intravenous
01
Overview
iPD1 CD19 eCAR T cells is an autologous, fourth-generation ("armored") chimeric antigen receptor (CAR) T-cell therapy developed by Peking University for the treatment of relapsed or refractory B-cell lymphoma. The therapy consists of patient-derived T cells genetically engineered using a lentiviral vector to express a second-generation CAR targeting the CD19 antigen (utilizing a 4-1BB costimulatory domain) alongside a short hairpin RNA (shRNA) cassette designed to knockdown the expression of Programmed Cell Death Protein 1 (PD1). By incorporating intrinsic PD1 inhibition, the therapy aims to prevent the induction of the PD1/PD-L1 immunosuppressive pathway upon T-cell activation, thereby enhancing the persistence and anti-tumor activity of the CAR T cells within the tumor microenvironment. It is currently being evaluated in Phase 1 clinical trials.
- Other names
- iPD1 CD19 eCAR T cellsiPD-1 CD19 eCAR T cellsiPD 1 CD19 eCAR T cellsAutologous Anti-CD19 4-1BB CAR T Cells With Cell-intrinsic PD1 InhibitioniPD1-CD19-eCAR-TiPD-1-CD19-eCAR-TiPD 1-CD19-eCAR-T
02
Targets
CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on iPD1 CD19 eCAR T cells (Peking University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iPD1 CD19 eCAR T cells (Peking University).